255 related articles for article (PubMed ID: 29119473)
1. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.
Carballo-Diéguez A; Giguere R; Dolezal C; Leu CS; Balán IC; Brown W; Rael C; Richardson BA; Piper JM; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla CD; Lama JR; McGowan I; Cranston RD;
AIDS Behav; 2017 Dec; 21(12):3336-3345. PubMed ID: 29119473
[TBL] [Abstract][Full Text] [Related]
2. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
[TBL] [Abstract][Full Text] [Related]
3. An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate.
McGowan IM; Kunjara Na Ayudhya RP; Brand RM; Marzinke MA; Hendrix CW; Johnson S; Piper J; Holtz TH; Curlin ME; Chitwarakorn A; Raengsakulrach B; Doncel G; Schwartz JL; Rooney JF; Cranston RD
AIDS Res Hum Retroviruses; 2022 Apr; 38(4):279-287. PubMed ID: 34541872
[TBL] [Abstract][Full Text] [Related]
4. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
[TBL] [Abstract][Full Text] [Related]
5. MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.
Cranston RD; Lama JR; Richardson BA; Carballo-Diéguez A; Kunjara Na Ayudhya RP; Liu K; Patterson KB; Leu CS; Galaska B; Jacobson CE; Parikh UM; Marzinke MA; Hendrix CW; Johnson S; Piper JM; Grossman C; Ho KS; Lucas J; Pickett J; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu AY; Mayer KH; Zorrilla C; Schwartz JL; Rooney J; McGowan I;
Clin Infect Dis; 2017 Mar; 64(5):614-620. PubMed ID: 27986684
[TBL] [Abstract][Full Text] [Related]
6. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
[TBL] [Abstract][Full Text] [Related]
8. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
10. Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017).
Liu AY; Norwood A; Gundacker H; Carballo-Diéguez A; Johnson S; Patterson K; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Mayer KH; Zorrilla C; Buchbinder S; Piper JM; Lama JR; Cranston RD
J Acquir Immune Defic Syndr; 2019 Aug; 81(5):516-520. PubMed ID: 31299013
[TBL] [Abstract][Full Text] [Related]
11. Acceptability of Antiretroviral Pre-exposure Prophylaxis from a Cohort of Sexually Experienced Young Transgender Women in Two U.S. Cities.
Restar AJ; Kuhns L; Reisner SL; Ogunbajo A; Garofalo R; Mimiaga MJ
AIDS Behav; 2018 Nov; 22(11):3649-3657. PubMed ID: 29713838
[TBL] [Abstract][Full Text] [Related]
12. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
[TBL] [Abstract][Full Text] [Related]
13. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
14. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
Noret M; Balavoine S; Pintado C; Siguier M; Brun A; Bauer R; Loze B; Leplatois A; Aslan A; Moudachirou K; Delaugerre C; Rozenbaum W; Molina JM
AIDS; 2018 Sep; 32(15):2161-2169. PubMed ID: 30212403
[TBL] [Abstract][Full Text] [Related]
15. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.
Buchbinder SP; Glidden DV; Liu AY; McMahan V; Guanira JV; Mayer KH; Goicochea P; Grant RM
Lancet Infect Dis; 2014 Jun; 14(6):468-75. PubMed ID: 24613084
[TBL] [Abstract][Full Text] [Related]
16. Trajectory of use over time of an oral tablet and a rectal gel for HIV prevention among transgender women and men who have sex with men.
Leu CS; Giguere R; Bauermeister JA; Dolezal C; Brown W; Balán IC; Richardson BA; Piper JM; Lama JR; Cranston RD; Carballo-Diéguez A
AIDS Care; 2019 Mar; 31(3):379-387. PubMed ID: 30318905
[TBL] [Abstract][Full Text] [Related]
17. Preference for daily versus on-demand pre-exposure prophylaxis for HIV and correlates among men who have sex with men: the China Real-world Oral PrEP Demonstration study.
Zhang J; Xu JJ; Wang HY; Huang XJ; Chen YK; Wang H; Chu ZX; Hu QH; He XQ; Li Y; Zhang LK; Hu ZL; Bao RT; Li SC; Li H; Ding HB; Jiang YJ; Geng WQ; Sylvia S; Shang H;
J Int AIDS Soc; 2021 Feb; 24(2):e25667. PubMed ID: 33586841
[TBL] [Abstract][Full Text] [Related]
18. Acceptability of oral versus rectal HIV preexposure prophylaxis among men who have sex with men and transgender women in Peru.
Peinado J; Lama JR; Galea JT; Segura P; Casapia M; Ortiz A; Montano SM; Kochel T; Sánchez J
J Int Assoc Provid AIDS Care; 2013; 12(4):278-83. PubMed ID: 23422742
[TBL] [Abstract][Full Text] [Related]
19. Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial.
Mehrotra ML; Westreich D; McMahan VM; Glymour MM; Geng E; Grant RM; Glidden DV
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):e94-e98. PubMed ID: 31192894
[No Abstract] [Full Text] [Related]
20. Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).
Defechereux PA; Mehrotra M; Liu AY; McMahan VM; Glidden DV; Mayer KH; Vargas L; Amico KR; Chodacki P; Fernandez T; Avelino-Silva VI; Burns D; Grant RM;
AIDS Behav; 2016 Jul; 20(7):1478-88. PubMed ID: 26078115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
